Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose
Abstract
Several software tools are available that facilitate the use of the NONMEM software and extend its functionality. This tutorial shows how three commonly used and freely available tools, Pirana, PsN, and Xpose, form a tightly integrated workbench for modeling and simulation with NONMEM. During the tutorial, we provide some guidance on what diagnostics we consider most useful in pharmacokinetic model development and how to construct them using these tools.
CPT: Pharmacometrics & Systems Pharmacology (2013) 2, e50; doi:10.1038/psp.2013.24; advance online publication 26 June 2013
BACKGROUND
Started in the early 1980s with the development of the NONMEM (acronym based on “NON‐linear Mixed‐Effects Modeling”) software,1 “population analysis” has proven to be extremely useful within pharmacometrics, both in the development of new drugs2 and the improvement of therapy with approved drugs.3 Development of the NONMEM software continues, and although over time several other modeling software tools have become available, NONMEM is still regarded as the gold standard within the pharmacometric community: a recent survey identified NONMEM (together with PsN)4 as the most frequently used software tool by far.5 Modeling and simulation (M&S) in clinical pharmacology, and the use of NONMEM in particular, however, has a steep learning curve for most starting researchers. This is partially because of the fact that NONMEM is invoked from the command line, and models are implemented using a Fortran‐derived syntax (NM‐TRAN). In addition, at its core, NONMEM performs only model estimation (or simulation), and the implementation of essential diagnostic tools such as bootstrap analyses and the creation of goodness‐of‐fit plots are left to the modeler. Therefore, alongside the development of NONMEM, many third‐party tools have been developed that facilitate the use of NONMEM by providing tools for organization and automation. In this tutorial, we will demonstrate the use of some of the most widely used auxiliary software tools: PsN, Xpose,6 and Pirana.7 All three tools are released under an open‐source license and are freely available (except for the commercial use of Pirana, for which a commercial license is required). Separately, each tool offers useful functionalities, but there is a synergistic benefit as well when used together.
The aim of this tutorial is to show how these three tools provide a comprehensive workbench for M&S. This will be performed by showing examples of the most often encountered steps in pharmacokinetic (PK) model development, i.e., a covariate modeling procedure and model evaluation using residual‐ and simulation‐based diagnostics. However, the aim of the tutorial is not to provide guidance on how to perform a population PK analysis but strictly on these software tools. A detailed overview of important aspects in population PK analyses has recently been presented in this journal, and we refer the reader to that article for guidance.8 The current tutorial is structured in three parts: first, a brief introduction to these software tools is given explaining their basic purpose. In the main part of the tutorial, we show how a typical PK model‐building analysis is performed with these tools and NONMEM. At the end of the tutorial, several interesting additional features are highlighted for each specific tool. We will assume the reader is already somewhat familiar with NONMEM, although we have made efforts to present and discuss the tools in a general manner wherever possible. All of the presented models, data sets, output, and diagnostic plots are available in the Supplementary Table S1 online.
SOFTWARE
In this tutorial, we will use NONMEM 7.2, Pirana 2.7.0, PsN 3.5.3, and Xpose 4.3.5. It is likely that the future versions will behave similarly, but in earlier versions, not all functions presented here may be available. We will show screenshots taken from Windows, but all programs discussed here function similarly on all major operating systems.
NONMEM
NONMEM9 is a modeling software that allows the user to estimate parameters in mixed‐effects models (“population approach”) on the basis of maximum‐likelihood or Bayesian techniques that use either gradient or stochastic estimation methods. NONMEM translates model code written in a unique Fortran‐based syntax (NM‐TRAN) into pure Fortran code, which is then compiled and executed. NONMEM is currently developed by ICON Development Solutions (http://www.iconplc.com/technology/products/nonmem/) under a proprietary software license.
PsN
PsN4 is a combination of tools for performing advanced M&S with NONMEM. It allows the implementation of bootstraps, visual predictive checks (VPCs), and many other useful functionalities. PsN is written in Perl (and needs Perl installed, freely available for all major operating systems) and is operated from the command line. Development started in 2000, and updates have been released with regular intervals.
Xpose
Xpose6 is a tool for plotting and analyzing NONMEM output, developed as a module for the R software (http://cran.r‐project.org/, open‐source, S‐based statistical software). The tools in Xpose can be used from the R command line or from a text‐based menu system in R. Xpose was first released in 1998 and was initially developed for S‐Plus. The current version (main version number 4) is, however, released exclusively for R and builds on the lattice module for plotting. Both PsN and Xpose are developed at the Uppsala University and are released under an open‐source license (GNU v2).
Pirana
Pirana7 is a graphical user interface for NONMEM, PsN, and Xpose/R. It has functionality for model management, model execution, output generation, interpretation of results, and includes many other tools. Development of Pirana started in 2007 at the Netherlands Cancer Institute/Slotervaart Hospital (Amsterdam, The Netherlands) and is currently continued by Pirana Software & Consulting BV (http://www.pirana‐software.com). Pirana is released under an open‐source license (Creative Commons) for academic users as well as a commercial license.
TUTORIAL
In this tutorial, file and folder names are shown in italic, Pirana actions are shown red‐italic, while commands, arguments, NONMEM syntax, and screen output are shown in fixed‐width font. We will step through an example model‐building exercise, with the intent of showing how to create, manage, and evaluate PK models for a given data set. The PK data set used in this tutorial (pktab1) is available in the Supplementary Table S1 online and contains plasma concentration data obtained from a simulated clinical trial of a novel i.v. drug, performed in 50 patients, measured at 8 time points. All model files that are mentioned in this article are also available online and can be used as reference. Make sure that all software is installed correctly, and NONMEM runs can be started from both PsN and Pirana (visit the respective websites for installation instructions) and that the Xpose4 package is installed in R. Create a folder for this analysis somewhere on your hard‐drive, and put pktab1 in this folder. Browse to this folder in Pirana and save it as the project “TutorialPSP” (button 4 in Figure 1). As a starting point for NONMEM models, it is often easiest to use the PK model wizard in Pirana or start from one of the models available in the model library. Start the wizard dialog window in Pirana (Tools → Wizards), choose the PK model wizard, and explore the options. However, for this tutorial, we have already provided the first model (run1.mod): copy the model run1.mod from the Supplementary Table S1 online to the folder you created. This model should now be visible in the Pirana main model list when you direct Pirana to the right folder (if not, refresh Pirana; button 5 in Figure 1). If you run from a model created by the wizard, make sure that the columns in the data set match up exactly with the records specified in the $INPUT record in the model file. For the provided run1.mod, this has already been done.

Pirana main window.
First runs
If we would invoke the native NONMEM run script, we would run, e.g., nmfe72 run1.mod run1.lst, but Pirana automates this in a dialog window: (select model → right click → NONMEM → nmfe). Several options are available to configure how and where (local or on a cluster) to run the model, or whether to submit it to a job scheduler. If you choose to run your models in Pirana through nmfe, you need to configure a NONMEM installation in Pirana (Settings → NONMEM). Select the quick‐find option to scan your hard‐drive for common installation locations for NONMEM. If NONMEM is not found there yet, specify the location yourself.
In this tutorial, we will, however, not use nmfe, but only PsN to run models. There are multiple benefits of using PsN's execute over the regular nmfe command, the main ones being that models are run in separate folders, runs can be restarted automatically upon crashes and unsuccessful minimizations, and initial estimates can be tweaked. Select the model and right click → PsN → execute. Pirana will show a similar dialog window as shown for nmfe, but now the command line for PsN's execute tool is shown (Figure 2). For our first run, we will use the default command: execute run1.mod. After clicking the run button, if PsN and Pirana are set up correctly, a console window will open with the following message:
-
Starting 1 NONMEM executions. 1 in parallel.
-
S:1 .. ,

PsN dialog window.
which indicates that one model estimation has been started. The actual NONMEM process will run in a subfolder created by PsN. By default, this will be /modelfit_dir1, but a custom folder name can be specified using the ‐dir argument. If the argument ‐model_dir_name is specified, PsN will automatically choose an informative folder name, in this case /run1.mod.dir.1. Check that inside the folder created by PsN, a subfolder is created in which the NONMEM process actually runs (/NM_run1). In Pirana, PsN folders are hidden by default, as they may quickly clutter the model overview. To unhide them again, select either “PsN folders” or “All folders” from the folder selector (button 7 in Figure 1). Many additional arguments can be supplied to PsN commands to customize how PsN runs the NONMEM model, e.g.:
-
execute run1.mod -dir=test1 –retries=3 -parafile=mpi6.pnm –nm_version=nm72,
which will run model run1.mod in the folder /test1. PsN is also instructed now to run using NONMEM version 7.2, parallelized using MPI (specified in configuration file mpi6.pnm) and to retry three times if the model does not converge in the initial run, each time changing the initial estimates of the parameters. A list of all available arguments including help information is available from the PsN dialog window in Pirana (Figure 2), which is similar to using the –h and –help arguments on the command line. In the PsN configuration file (psn.conf), a list of default arguments can be supplied as well, so commonly used arguments do not have to be repeated on the command line.
Results evaluation
After estimation has been completed, refresh the Pirana main overview again. Basic results are now shown for the run, such as the objective function value (OFV), whether minimization was successful (S), and whether the covariance step was successful (C). If the run was successful, PsN will automatically copy back the results file (run1.lst) and the produced output tables (sdtab1, patab1) to the parent folder, which are then parsed by Pirana upon refreshing. Select the model again, and now select the Estimates tab from the right section of the Pirana window (11 in Figure 1). The right section will then show the parameter estimates for this run. A more detailed overview that will, e.g., show full random effect blocks can be opened from here. Create a run summary in Word format (alternatives are HTML, plain text, or LaTeX), from the menu → Results → Run Reports → Word.
Diagnostic plots are a main decision tool in pharmacometric model development, in which a distinction can be made between residual‐based diagnostics (goodness‐of‐fit plots based on residuals plotted vs. time or model predictions) and simulation‐based diagnostics (e.g., VPC). Obviously, no strict rule should be applied here, but in our experience, residual‐based diagnostics are more useful in the first stages of model development, whereas simulation‐based diagnostics are more useful in the latter stages of model development. Depending on what part of the model is diagnosed, different diagnostic plots will be useful, and most likely, no single plot will suffice to evaluate model fit. Suggestions for diagnostic plots for specific model parts are shown in 1. Note that this list is not exhaustive, and in addition, more specific plots may be required for appropriate diagnosis.
For the current analysis, we will first have a look at some basic, residual‐based goodness‐of‐fit plots. A general model diagnostic is the plot of weighted residuals vs. time, or vs. model predictions. For models run with the conditional estimation method (FOCE), it is most appropriate to use conditional weighted residuals (CWRES).10 Use the Xpose graphical user interface (GUI) within Pirana to create these plots (Figure 3): select model → right click → Xpose → Xpose GUI. Add the plot cwres.vs.pred and cwres.vs.idv to the list of plots, and possibly some additional goodness‐of‐fit plots (a list of useful Xpose plots is given in 2). In these plots, you should observe an obvious pattern in the residuals. It may not be obvious immediately what is the cause of the misspecification, but a look at the individual plots (ind.plots) probably gives more insight: the model seems to be missing the bi‐phasic nature of the observed data. Therefore, in the next step, we will add distribution of drug into a peripheral compartment to our PK model, but first, we will briefly discuss how to keep track of model development.

Xpose graphical user interface in Pirana.
- DataInspector: a quick and flexible method for creating diagnostic plots based on NONMEM output, or checking input data sets. Select the DataInspector for run1.mod (right click → Model → Open DataInspector). Pirana will ask you now which input‐ or output file to open, choose the file sdtab1. In the DataInspector window, the variables on the x and y axes can be easily changed to any variable in the data set, and filters can be applied on patient ID, or on any other variable. From this window, R‐code can be generated that will recreate the same graph in R.
- R‐script library: Pirana comes bundled with a library of diagnostic R scripts, which can be run automatically from Pirana. Select a model and select one of the R scripts from the Scripts Tab, e.g., Basic GOF → DV vs IPRED, and then select Run script from the buttons above the list. The requested plot will be created and opened in a pdf document. Created plots will be listed in the “Reports” tab (10 in Figure 1). The standard scripts bundled with Pirana can be extended and customized easily, but that is beyond the scope of this tutorial. Please refer to the manual and default scripts for guidance.
- Xpose menu system in R: The Xpose menu system can be started from Pirana (right click → Xpose → Start Xpose menu in R), or manually from an R session by invoking:
-
library(xpose4)
-
xpose4()
Xpose will then ask for the run number, which is used to determine which tables to import. Note that to use Xpose, NONMEM needs to be instructed to output tables that adhere to a specific naming and structure (Supplementary Table S1 online, or the Xpose Web site). If you did not use the Pirana model wizard to create the tables, add them manually in the NONMEM model file, using:
-
$TABLE ID TIME IPRED IWRES EVID MDV NOPRINT ONEHEADER FILE=sdtab1
From the Xpose menu system, goodness‐of‐fit plots can be created, e.g., browse to “4: Goodness‐of‐fit plots” and then “2: Basic goodness‐of‐fit plots.”
Model management in Pirana
In M&S projects in both academia and industry, it is essential to keep track of the model development history. Pirana and PsN offer a tool to aid the modeler with this through the run record. The run record entails a standardized way of keeping track of model meta‐information such as the “parent” model, a description, and/or a label for the model, and other information about the model components. We consider it good modeling practice to create a new model file for every change that is made to a model.
Duplicate the first model in Pirana (right click on run1.mod actions → File actions → duplicate). In the dialog that will open up, run2.mod is suggested as new model file name, and we can select which model is the reference model for this model (run1.mod), and optionally update the initial estimates with the parameter estimates from the reference model. The model description and other meta‐information are stored in the model file itself using the run record syntax (also see http://psn.sourceforge.net/pdfdocs/runrecord_userguide.pdf). Pirana can show the main model overview as a list or as a tree (button 6 in Figure 1) and can export a copy of the run record to various formats including comma separated (csv) files, HTML files, and Word documents (Results → Run records), or create an interactive visualization of the model development tree or “visual run record”11 such as that shown in Figure 4 (Results → Run records → Visual run record).

Visual run record example. Green indicates a significant improvement in fit, red indicates a worsening, yellow indicates approximate identical fit (ΔOFV < ±3.84), and gray indicates a noncomparable child model (e.g., change in dataset). The blue line is the path to the final model, whereas a dashed line indicates a nonnested model. OFV, objective function value.
After duplication, the model run2.mod will be shown in the model overview and opened in the editor, where we will now add a peripheral compartment to the model error model: change $SUBROUTINE to use ADVAN3 and TRANS4, change the parameter V into V1, and add to $PK:
-
Q = THETA(3)
-
V2 = THETA(4)
Of course, initial estimates for the intercompartmental distribution (Q) and peripheral compartment (V2) have to be specified as well in $THETA. For now, we chose to run this model without IIV on these parameters. Run this model using execute, evaluate the drop in objective function, and compare the diagnostic plots for run2 to those made for run1. You should encounter a considerable drop in the OFV and find that the diagnostic residual plots show much improved model fit.
Furthermore, we will diagnose the residual error model, for which an important diagnostic plot is that of absolute individual weighted residuals (|IWRES|) vs. individual predictions (IPRED). For a true model, the distribution of absolute residuals should be similar over the whole range of the x‐axis variable. If a homoscedastic error structure (additive error) was implemented in run1.mod and run2.mod, the plot will show larger residuals at higher individual predictions. This should therefore lead you to conclude that a heteroscedastic (combined proportional and additive) error model should provide a better description of the data. Therefore, create a new model (run3.mod) based on run2.mod and implement a combined error model using e.g.:
-
Y = IPRED * (1+EPS(1)) + EPS(2)
-
W = SQRT(IPRED**2*SIGMA(1,1)**2 + SIGMA(2,2)**2)
-
IWRES = (DV-IPRED)/W
It must be noted that the plot mentioned above is only informative at low ε‐shrinkage (as a rule of thumb, at ε‐shrinkage greater than ~5%, this plot loses informativeness).12 In cases of higher shrinkage, plots of CWRES vs. individual predictions (IPRED), or IWRESnpde13 vs. IPRED are more informative. The diagnostic plots as well as the significant drop in OFV indicate that the combined error model provides better fit.
Covariate model
The data set pktab1 contains three continuous covariates: weight (WT), creatinine clearance (CRCL), AGE, and two binary covariates: SEX and study center (CENT). Because the number of covariates is low (5), one might choose to test these covariates manually. However, in the next step of this tutorial, we will perform stepwise covariate modeling (scm) in PsN, to demonstrate this automated method. In the first phase of the scm, covariates are added to the base model in a stepwise manner based on statistical significance (decrease in OFV). In a second “backward elimination” phase, covariates are then removed from the final model obtained in the first phase, if removal of the covariate does not result in significantly worse fit. The backward step is typically done at a higher significance level. Like all PsN tools, the scm can be run from the command line or from Pirana, in a similar way as done before for execute. However, the scm tool requires that a configuration file is created first. Several examples of configuration files are available on the PsN Web site, but here we will create one using the wizard in Pirana (Tools → Wizards → scm configuration file). Create a configuration file, with the filename psp.scm, in which all covariates are tested on both CL and V1, at a significance level of 0.1 (forward step) and 0.05 (backward step) and restrict the analysis to linear relationships (set the relationships argument to “1,2”). Check that the correct covariates are included; the ones shown in the wizard are only placeholders. If you are not sure on the correct syntax of the scm file, please have a look at the provided annotated configuration file (psp.scm in the Supplementary Data online). Before starting the scm, duplicate run3.mod to run4.mod, and remove any $TABLE records that are present. Start the scm from the PsN dialog window using this command:
-
scm psp.scm –model=run4.mod
After the scm has completed, PsN will compile an output file called scmlog.txt in the scm folder. Open this file and interpret the information, it holds the results for all tests performed in the scm and shows how the final covariate model was constructed. You should find that four covariate relationships are significant: CRCL on CL, WT on CL, WT on V, and SEX on V. This will be our “final model” from the covariate model‐building step. If you did not find these results, compare your results with those provided in the Supplementary Data online.
More elaborate covariate model‐building techniques based on the scm are available in PsN as well, such as the cross‐validated scm (xv_scm),14 and the bootstrap of the scm (boot_scm).15 These tools provide more details on the predictive ability of the model, and on selection bias and expected covariate model size, respectively. They can also be run on linearized versions of the model, to reduce the computational workload.16 Other covariate modeling tools that are available in PsN include the lasso17 and the fixed random effects model (FREM),18 whereas in Xpose, the gam and bootstrap of the gam (bootgam) are implemented.6 All of these methods have certain advantages and drawbacks, which are however beyond the scope of this article.
Final model
If the scm completed successfully, you will find a folder called final_models inside the scm folder created by PsN. Inside that folder, locate the final model with included covariate relations and copy that to the main model folder, renaming it to run5.mod. We will use this model to perform some more elaborate diagnostic evaluation, i.e., we will get bootstrap estimates for our parameters and create a VPC. Therefore, first open the PsN bootstrap dialog window (Right click → PsN → Model diagnostic → bootstrap). A required argument to the bootstrap command is the –samples argument, which specifies how many bootstrap samples should be drawn. More samples will make the bootstrap estimates and percentile estimates more precise; however, at the expense of increased computation times. The recommended number of samples for an analysis will depend on what statistic is desired by the modeler. For obtaining bootstrap means of the parameter estimates, 100 samples may be enough, but to obtain accurate 5th and 95th percentiles, 1,000 or more are required to obtain precise estimates. After the bootstrap is finished (on a single core, a bootstrap of 200 samples may easily take an hour for this model), the results from the bootstrap are available in the bootstrap folder, in the files raw_results_run5.csv and bootstrap_results.csv. Open these files and interpret the output: are the parameters estimated with adequate precision? In Pirana, select the bootstrap folder created by PsN and run the R script to create plots of parameter distributions (Scripts tab → PsN → Bootstrap results), which facilitates evaluation and interpretation of these bootstrap results.
Earlier in this tutorial, we presented how basic goodness‐of‐fit plots can be created in Pirana and Xpose. Now, we will use all three tools to create a VPC of the final model (run5.mod). A VPC is an internal validation tool, i.e., it shows how well the model predicts the data on which the model was conditioned. It visualizes the median model prediction, the variability between patients and within patients (5th and 95th percentiles), and the uncertainty around the predicted percentiles.19 Before creating a VPC, we would like to stress a few points. First, in VPCs, it is important to show the uncertainty around the model‐predicted percentiles, instead of presenting only lines indicating the point estimates of the percentiles. Signs of model improvement are when the confidence areas of the simulated percentiles encompass more of the observation percentiles, but also when the confidence intervals themselves are shrinking (while still encompassing the observation percentiles). Furthermore, because the VPC shows summary statistics (percentiles) of observations and predictions for binned data, the binning method is an important consideration. To avoid inflation of the uncertainty around the summary statistics, each bin should contain an adequate amount of observations. A quick rule of thumb is that there should not be more bins than the number of observations per individual. PsN currently incorporates several binning approaches: manual bin specification (‐bin_array=x,y,z,etc), binning into an equal number of data points per bin (‐bin_by_count=1 –no_of_bins=#), or spacing the bins equally over the x‐axis (‐bin_by_count=0, ‐no_of_bins=#). Of note, binning across a large variability in dose and/or influential covariates can diminish the diagnostic value of a VPC. One approach to overcome this is to stratify the VPC by the covariate, but this is not always possible, e.g., due to limited data per stratum. Moreover, when data arises from studies with adaptive designs (e.g., dose adjustments), VPCs are misleading unless the adaptation protocol is included in the model. The prediction‐corrected VPC offers a solution to these problems while retaining the visual interpretation of the traditional VPC.20 Prediction‐corrected VPCs can be constructed by adding the argument –pred_corr to the PsN VPC command.
VPCs can be made in Pirana using the PsN dialog window (right click → PsN → model evaluation → VPC), or from the command line. As discussed above, essential arguments to pass to the VPC are the number of samples and the binning method. Increasing the number of samples will increase the accuracy of the summary statistics for the simulation and their uncertainty interval (but it will not decrease the uncertainty interval itself). Start the VPC tool using
vpc –samples=500 –no_of_bins=8 –bin_by_count=1 run5.mod
The first of the two NONMEM runs that are started will only output a table with the necessary (observation) data for the VPC, it does not perform parameter estimation. The other model runs repeated Monte Carlo simulations of the model, using the same data set design as the original. After the two NONMEM runs have finished, PsN will process the output, bin the simulated and observed data, calculate the percentiles and confidence intervals for each bin, and export a csv file with the summary statistics. This csv‐file can then be processed by Xpose and turned into a VPC‐plot, which can be automated from Pirana using the Xpose GUI as described before, or using the R scripts library. Both the approaches will create and open a pdf file with the VPC (see example in Figure 5). Using the latter approach, this is done as follows: select the VPC‐folder created by PsN, and open the Scripts tab on the right. In the list of R scripts, choose Xpose → VPC → Basic_log_y.R. A pdf file with the VPC will be generated and opened from Pirana. As an exercise, try to create the same plot using the Xpose GUI in Pirana as well: select the model in the main overview and Right click → Xpose → Xpose GUI.

Visual predictive check. A visual predictive check for run3.mod. The solid line connects the observed median values per bin, whereas the dashed lines represent the observed 5th and 95th percentile of the observations. Blue areas indicate the 95% CIs of the 5th and 95th percentile of the predicted (simulated) value, whereas the red area indicates the CI of the median. The logarithmic y‐axis makes it easier to judge correspondence between observed and predicted, especially in the terminal part of the plot. For this problem, it would be advisable to make a separate plot for the initial part of the VPC (0–4 h), because it is difficult to see the accordance between observed and predicted in that area. The VPC would also be clearer in the initial part if it would have been plotted without the observations (observed percentiles only).
Because only limited space is available for this tutorial, we will not demonstrate other diagnostics. We will however create a run record of the model development: in the menu bar, click Results → Run records → Detailed run record (csv). This will create and open a csv file containing run numbers, descriptions, other meta‐information, and run results. If the file does not open automatically, please look it up in the “Files” tab on the right and double click it. As a final step in our PK model development, select the final model again and bundle that model file, the associated result files and output files and the VPC folder into a zip file (Right click → File actions→ Compress to zip‐file). Moreover, create a bundled report of the goodness‐of‐fit plots for the final model (in the Reports tab, select the desired pdf's and click Bundle into… → <output format>).
Additional features
For all three software tools presented here, we have only scratched the surface of possibilities. The reader is encouraged to explore more advanced functionality using the documentation available on the respective websites. We will highlight a few examples of more advanced features for the three programs below.
PsN. The simulation and re‐estimation (sse) tool can be used to evaluate trial designs, e.g., to evaluate whether model parameters can be estimated with adequate precision under the intended or alternative experimental designs or with alternative models. It is also useful for evaluating fundamental modeling aspects, e.g., to evaluate how model diagnostics perform under given designs. Another interesting tool for design evaluation, specifically for the calculation of study power and number of study subjects required, is Monte Carlo Mapped Power (mcmp).21 In this tool, which is also based on simulation and re‐estimation, the individual OFVs calculated in NONMEM are exploited to evaluate designs in a more rapid way than using sse. Case deletion diagnostics (cdd) is a tool that can be used in the final stages of model development to investigate whether model fit depends more heavily on particular strata of the data set. The most important PsN functions are listed in 3.
Xpose. In this tutorial, we showed how to create goodness‐of‐fit plots from the Xpose menu system, and from the Xpose interface in Pirana (VPC). However, the most efficient way to use Xpose, especially when doing repetitive jobs, is to use scripts to create the desired goodness‐of‐fit plots. A list of useful Xpose functions is given in 2, whereas a more complete overview of functions and example scripts (“bestiarium”) is available on the Xpose website. The default plots in Xpose can be extended and modified in various ways. First, most Xpose functions take arguments that alter the implementation of the plot. The looks of the plots can also be changed by directly passing lattice arguments to the Xpose function. Second, the input variables can be altered easily to allow creation of nondefault plots. For example, to create a plot of a covariate METAB vs. IDV instead of DV vs. IDV, we can “trick” Xpose into using METAB as DV while maintaining the plot characteristics:
-
> change.xvardef(xpdb, “dv”) <- c(“METAB”)
-
> xplot <- dv.vs.idv(xpdb)
-
> print(xplot)
Finally, since Xpose is an open‐source R module, it is possible to modify the Xpose functions directly, if further modifications are required.
Pirana. A model translator is included that can translate any NONMEM model (written in an NM‐TRAN ADVAN subroutine) to differential equation code for R (using deSolve library), Berkeley Madonna (software dedicated to ODE simulations), or Matlab/PopED.22 Note that many functions in Pirana can be extended and customized by the user, such as the R‐scripts library and the wizards. Pirana can also be used for modeling on remote clusters (through ssh‐connections) and has native support for SGE, Torque, and Condor job schedulers.
CONCLUSION
In this tutorial, we presented a modeling workbench that incorporates three tools, which in our view make M&S with NONMEM more powerful, more efficient, and easier to perform. It is our intention to implement all new modeling techniques and diagnostics developed within our group into PsN, Xpose, and/or Pirana, so new versions are expected to be released on a regular basis.
Acknowledgments
The researchers in the Pharmacometrics Research Group are acknowledged for their input on the use of diagnostics in model development.
Conflict of interest
R.J.K. is owner of Pirana Software & Consulting BV, which provides commercial licensing of Pirana. The other authors declared no conflict of interest.
Citing Literature
Number of times cited according to CrossRef: 251
- Cornelis Smit, Roeland E. Wasmann, Sebastiaan C. Goulooze, Marinus J. Wiezer, Eric P.A. Dongen, Johan W. Mouton, Roger J.M. Brüggemann, Catherijne A.J. Knibbe, Population pharmacokinetics of vancomycin in obesity: Finding the optimal dose for (morbidly) obese individuals, British Journal of Clinical Pharmacology, 10.1111/bcp.14144, 86, 2, (303-317), (2020).
- Lucia Nogova, Christian Mattonet, Matthias Scheffler, Max Taubert, Masyar Gardizi, Martin L. Sos, Sebastian Michels, Rieke N. Fischer, Meike Limburg, Diana S.Y. Abdulla, Thorsten Persigehl, Carsten Kobe, Sabine Merkelbach‐Bruse, Jeremy Franklin, Heiko Backes, Roland Schnell, Dirk Behringer, Britta Kaminsky, Martina Eichstaedt, Christoph Stelzer, Martina Kinzig, Fritz Sörgel, Yingying Tian, Lisa Junge, Ahmed A. Suleiman, Sebastian Frechen, Dennis Rokitta, Dongsheng Ouyang, Uwe Fuhr, Reinhard Buettner, Jürgen Wolf, Sorafenib and everolimus in patients with advanced solid tumors and KRAS‐mutated NSCLC: A phase I trial with early pharmacodynamic FDG‐PET assessment, Cancer Medicine, 10.1002/cam4.3131, 9, 14, (4991-5007), (2020).
- Laurent M.A. Favié, Alwin D.R. Huitema, Marcel P.H. Broek, Carin M.A. Rademaker, Timo R. Haan, Henrica L.M. Straaten, Sinno H.P. Simons, Monique Rijken, Debbie H.G.M. Nuytemans, Toine C.G. Egberts, Floris Groenendaal, Lidocaine as treatment for neonatal seizures: Evaluation of previously developed population pharmacokinetic models and dosing regimen, British Journal of Clinical Pharmacology, 10.1111/bcp.14136, 86, 1, (75-84), (2020).
- Ida Netterberg, René Bruno, Ya‐Chi Chen, Helen Winter, Chi‐Chung Li, Jin Y. Jin, Lena E. Friberg, Tumor Time‐Course Predicts Overall Survival in Non‐Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow‐Up Time, CPT: Pharmacometrics & Systems Pharmacology, 10.1002/psp4.12489, 9, 2, (115-123), (2020).
- Mats Bue, Tomás Sou, Anna Sophie L. Okkels, Pelle Hanberg, Anders Thorsted, Lena E. Friberg, Torben L. Andersson, Kristina Öbrink-Hansen, Steffen Christensen, Population pharmacokinetics of piperacillin in plasma and subcutaneous tissue in patients on continuous renal replacement therapy, International Journal of Infectious Diseases, 10.1016/j.ijid.2020.01.010, 92, (133-140), (2020).
- Siyuan Wang, Xiao Zhu, Mengyi Han, Fangran Hao, Wei Lu, Tianyan Zhou, Mechanistic Pharmacokinetic/Pharmacodynamic Model of Sunitinib and Dopamine in MCF-7/Adr Xenografts: Linking Cellular Heterogeneity to Tumour Burden, The AAPS Journal, 10.1208/s12248-020-0428-5, 22, 2, (2020).
- Lénaïg Tanneau, Mats O. Karlsson, Elin M. Svensson, Understanding the drug exposure–response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug‐resistant tuberculosis, British Journal of Clinical Pharmacology, 10.1111/bcp.14199, 86, 5, (913-922), (2020).
- Theodoros Papathanasiou, Anders Strathe, Henrik Agersø, Trine Meldgaard Lund, Rune Viig Overgaard, Impact of dose‐escalation schemes and drug discontinuation on weight loss outcomes with liraglutide 3.0 mg: A model‐based approach, Diabetes, Obesity and Metabolism, 10.1111/dom.13985, 22, 6, (969-977), (2020).
- Jose Francis, Karen I. Barnes, Lesley Workman, Tamara Kredo, Lasse S. Vestergaard, Richard M. Hoglund, Pauline Byakika-Kibwika, Mohammed Lamorde, Stephen I. Walimbwa, Ifeyinwa Chijioke-Nwauche, Colin J. Sutherland, Concepta Merry, Kimberley K. Scarsi, Nyagonde Nyagonde, Martha M. Lemnge, Saye H. Khoo, Ib C. Bygbjerg, Sunil Parikh, Francesca T. Aweeka, Joel Tarning, Paolo Denti, An Individual Participant Data Population Pharmacokinetic Meta-analysis of Drug-Drug Interactions between Lumefantrine and Commonly Used Antiretroviral Treatment, Antimicrobial Agents and Chemotherapy, 10.1128/AAC.02394-19, 64, 5, (2020).
- Soyoung Kang, June Young Jang, Jongsung Hahn, Dasohm Kim, Jun Yeong Lee, Kyoung Lok Min, Seungwon Yang, Jin Wi, Min Jung Chang, Dose Optimization of Cefpirome Based on Population Pharmacokinetics and Target Attainment during Extracorporeal Membrane Oxygenation, Antimicrobial Agents and Chemotherapy, 10.1128/AAC.00249-20, 64, 5, (2020).
- Alan Faraj, Robin J. Svensson, Andreas H. Diacon, Ulrika S. H. Simonsson, Drug Effect of Clofazimine on Persisters Explains an Unexpected Increase in Bacterial Load in Patients, Antimicrobial Agents and Chemotherapy, 10.1128/AAC.01905-19, 64, 5, (2020).
- Helena Rabie, Tjokosela Tikiso, Janice Lee, Lee Fairlie, Renate Strehlau, Raziya Bobat, Afaaf Liberty, Helen McIlleron, Isabelle Andrieux-Meyer, Mark Cotton, Marc Lallemant, Paolo Denti, Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir, Antimicrobial Agents and Chemotherapy, 10.1128/AAC.01923-19, 64, 5, (2020).
- Norma A. Aréchiga-Alvarado, Susanna E. Medellín-Garibay, Rosa del C. Milán-Segovia, Arturo Ortiz-Álvarez, Martín Magaña-Aquino, Silvia Romano-Moreno, Population Pharmacokinetics of Amikacin Administered Once Daily in Patients with Different Renal Functions, Antimicrobial Agents and Chemotherapy, 10.1128/AAC.02178-19, 64, 5, (2020).
- Xia Li, Lisa Junge, Max Taubert, Anabelle Georg, Dominik Dahlinger, Chris Starke, Sebastian Frechen, Christoph Stelzer, Martina Kinzig, Fritz Sörgel, Ulrich Jaehde, Ulrich Töx, Tobias Goeser, Uwe Fuhr, A Novel Study Design Using Continuous Intravenous and Intraduodenal Infusions of Midazolam and Voriconazole for Mechanistic Quantitative Assessment of Hepatic and Intestinal CYP3A Inhibition, The Journal of Clinical Pharmacology, 10.1002/jcph.1619, 60, 9, (1237-1253), (2020).
- Xiao Zhu, David B. Finlay, Michelle Glass, Stephen B. Duffull, Evaluation of the profiles of CB1 cannabinoid receptor signalling bias using joint kinetic modelling, British Journal of Pharmacology, 10.1111/bph.15066, 177, 15, (3449-3463), (2020).
- Ali A. Alhadab, Richard C. Brundage, Population Pharmacokinetics of Sertraline in Healthy Subjects: a Model-Based Meta-analysis, The AAPS Journal, 10.1208/s12248-020-00455-y, 22, 4, (2020).
- Vibeke Klastrup, Anders Thorsted, Merete Storgaard, Steffen Christensen, Lena E. Friberg, Kristina Öbrink-Hansen, Population Pharmacokinetics of Piperacillin following Continuous Infusion in Critically Ill Patients and Impact of Renal Function on Target Attainment, Antimicrobial Agents and Chemotherapy, 10.1128/AAC.02556-19, 64, 7, (2020).
- Henrik Bjugård Nyberg, Andrew C. Hooker, Robert J. Bauer, Yasunori Aoki, Saddle-Reset for Robust Parameter Estimation and Identifiability Analysis of Nonlinear Mixed Effects Models, The AAPS Journal, 10.1208/s12248-020-00471-y, 22, 4, (2020).
- Bernard Ngara, Simbarashe Zvada, Tariro Dianah Chawana, Babill Stray-Pedersen, Charles Fungai Brian Nhachi, Simbarashe Rusakaniko, A population pharmacokinetic model is beneficial in quantifying hair concentrations of ritonavir-boosted atazanavir: a study of HIV-infected Zimbabwean adolescents, BMC Pharmacology and Toxicology, 10.1186/s40360-020-00437-y, 21, 1, (2020).
- Nan Zhang, Natasha Strydom, Sandeep Tyagi, Heena Soni, Rokeya Tasneen, Eric L. Nuermberger, Rada M. Savic, Mechanistic Modeling of Mycobacterium tuberculosis Infection in Murine Models for Drug and Vaccine Efficacy Studies , Antimicrobial Agents and Chemotherapy, 10.1128/AAC.01727-19, 64, 3, (2020).
- Keith T. Schmidt, Alwin D. R. Huitema, Thomas P. C. Dorlo, Cody J. Peer, Lisa M. Cordes, Linda Sciuto, Susan Wroblewski, Yves Pommier, Ravi A. Madan, Anish Thomas, William D. Figg, Population pharmacokinetic analysis of nanoparticle-bound and free camptothecin after administration of NLG207 in adults with advanced solid tumors, Cancer Chemotherapy and Pharmacology, 10.1007/s00280-020-04134-9, 86, 4, (475-486), (2020).
- Fernando Carreño, Victória Eteges Helfer, Keli Jaqueline Staudt, Laura Bem Olivo, Karina Paese, Fabíola Schons Meyer, Ana Paula Herrmann, Sílvia Stanisçuaski Guterres, Stela Mari Kuze Rates, Iñaki Trocóniz, Teresa Dalla Costa, Semi-Mechanistic Pharmacokinetic Modeling of Lipid Core Nanocapsules: Understanding Quetiapine Plasma and Brain Disposition in a Neurodevelopmental Animal Model of Schizophrenia, Journal of Pharmacology and Experimental Therapeutics, 10.1124/jpet.120.000109, 375, 1, (49-58), (2020).
- Alan Faraj, Oskar Clewe, Robin J. Svensson, Galina V. Mukamolova, Michael R. Barer, Ulrika S. H. Simonsson, Difference in persistent tuberculosis bacteria between in vitro and sputum from patients: implications for translational predictions, Scientific Reports, 10.1038/s41598-020-72472-y, 10, 1, (2020).
- Orwa Albitar, Rama Ballouze, Sabariah Noor Harun, Dzul Azri Mohamed Noor, Siti Maisharah Sheikh Ghadzi, Population Pharmacokinetic Modeling of Cyclosporine Among Malaysian Renal Transplant Patients: An Evaluation of Methods to Handle Missing Doses in Conventional Drug‐Monitoring Data, The Journal of Clinical Pharmacology, 10.1002/jcph.1670, 60, 11, (1474-1482), (2020).
- Yassine Kamal Lyauk, Trine Meldgaard Lund, Andrew C. Hooker, Mats O. Karlsson, Daniël M. Jonker, Integrated Item Response Theory Modeling of Multiple Patient-Reported Outcomes Assessing Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia, The AAPS Journal, 10.1208/s12248-020-00484-7, 22, 5, (2020).
- Mahmoud Tareq Abdelwahab, Rory Leisegang, Kelly E. Dooley, Jyoti S. Mathad, Lubbe Wiesner, Helen McIlleron, Neil Martinson, Ziyaad Waja, Matebogo Letutu, Richard E. Chaisson, Paolo Denti, Population Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in Pregnant South African Women with Tuberculosis and HIV, Antimicrobial Agents and Chemotherapy, 10.1128/AAC.01978-19, 64, 3, (2020).
- Henrik Bjugård Nyberg, Heather R. Draper, Anthony J. Garcia-Prats, Stephanie Thee, Adrie Bekker, Heather J. Zar, Andrew C. Hooker, H. Simon Schaaf, Helen McIlleron, Anneke C. Hesseling, Paolo Denti, Population Pharmacokinetics and Dosing of Ethionamide in Children with Tuberculosis, Antimicrobial Agents and Chemotherapy, 10.1128/AAC.01984-19, 64, 3, (2020).
- Xi-wei Ji, Feng Xue, Zi-sheng Kang, Wei Zhong, Isabelle Hui-san Kuan, Xi-ping Yang, Xiao Zhu, Yun Li, Yuan Lv, Model-Informed Drug Development, Pharmacokinetic/Pharmacodynamic Cutoff Value Determination, and Antibacterial Efficacy of Benapenem against Enterobacteriaceae , Antimicrobial Agents and Chemotherapy, 10.1128/AAC.01751-19, 64, 3, (2020).
- Nelleke Snelder, Sven Hoefman, Alberto Garcia-Hernandez, Hartmut Onkels, Tobias E. Larsson, Kirsten R. Bergmann, Population pharmacokinetics and pharmacodynamics of a novel vascular adhesion protein-1 inhibitor using a multiple-target mediated drug disposition model, Journal of Pharmacokinetics and Pharmacodynamics, 10.1007/s10928-020-09717-w, (2020).
- Femke de Velde, Brenda C. M. de Winter, Michael N. Neely, Walter M. Yamada, Birgit C. P. Koch, Stephan Harbarth, Elodie von Dach, Teun van Gelder, Angela Huttner, Johan W. Mouton, Population Pharmacokinetics of Imipenem in Critically Ill Patients: A Parametric and Nonparametric Model Converge on CKD-EPI Estimated Glomerular Filtration Rate as an Impactful Covariate, Clinical Pharmacokinetics, 10.1007/s40262-020-00859-1, (2020).
- Aurelia H. M. de Vries Schultink, Kees Bol, Robert P. Doornbos, Anastasia Murat, Ernesto Wasserman, Thomas P. C. Dorlo, Jan H. M. Schellens, Jos H. Beijnen, Alwin D. R. Huitema, Population Pharmacokinetics of MCLA-128, a HER2/HER3 Bispecific Monoclonal Antibody, in Patients with Solid Tumors, Clinical Pharmacokinetics, 10.1007/s40262-020-00858-2, (2020).
- Tae Hwan Kim, Xun Tao, Bartolome Moya, Yuanyuan Jiao, Kari B. Basso, Jieqiang Zhou, Yinzhi Lang, Dhruvitkumar S. Sutaria, Alexandre P. Zavascki, Afonso L. Barth, Stephanie M. Reeve, Herbert P. Schweizer, Deanna Deveson Lucas, John D. Boyce, Robert A. Bonomo, Richard E. Lee, Beom Soo Shin, Arnold Louie, George L. Drusano, Jürgen B. Bulitta, Novel Cassette Assay To Quantify the Outer Membrane Permeability of Five β-Lactams Simultaneously in Carbapenem-Resistant Klebsiella pneumoniae and Enterobacter cloacae , mBio, 10.1128/mBio.03189-19, 11, 1, (2020).
- E Leegwater, B V C Kraaijenbrink, D J A R Moes, I M Purmer, E B Wilms, Population pharmacokinetics of ceftriaxone administered as continuous or intermittent infusion in critically ill patients, Journal of Antimicrobial Chemotherapy, 10.1093/jac/dkaa067, (2020).
- Maddalena Centanni, Lena E. Friberg, Model-Based Biomarker Selection for Dose Individualization of Tyrosine-Kinase Inhibitors, Frontiers in Pharmacology, 10.3389/fphar.2020.00316, 11, (2020).
- Lin Yang, Hui Wu, Brenda C. M. de Winter, Chang-cheng Sheng, Hong-qiang Qiu, Yu Cheng, Juan Chen, Qiu-ling Zhao, Jing Huang, Zheng Jiao, Rui-xiang Xie, Pharmacokinetics and pharmacogenetics of high-dose methotrexate in Chinese adult patients with non-Hodgkin lymphoma: a population analysis, Cancer Chemotherapy and Pharmacology, 10.1007/s00280-020-04058-4, (2020).
- Tomás Sou, Irena Kukavica-Ibrulj, Roger C. Levesque, Lena E. Friberg, Christel A.S. Bergström, Model-Informed Drug Development in Pulmonary Delivery: Semimechanistic Pharmacokinetic–Pharmacodynamic Modeling for Evaluation of Treatments against Chronic Pseudomonas aeruginosa Lung Infections , Molecular Pharmaceutics, 10.1021/acs.molpharmaceut.9b00968, (2020).
- Lina Keutzer, Ulrika S. H. Simonsson, Individualized Dosing With High Inter-Occasion Variability Is Correctly Handled With Model-Informed Precision Dosing—Using Rifampicin as an Example, Frontiers in Pharmacology, 10.3389/fphar.2020.00794, 11, (2020).
- Oskar Clewe, Alan Faraj, Yanmin Hu, Anthony R. M. Coates, Ulrika S. H. Simonsson, A model-based analysis identifies differences in phenotypic resistance between in vitro and in vivo: implications for translational medicine within tuberculosis, Journal of Pharmacokinetics and Pharmacodynamics, 10.1007/s10928-020-09694-0, (2020).
- Rob Heine, Ron J. Keizer, Krista Steeg, Elise J. Smolders, Matthijs Luin, Hieronymus J. Derijks, Cornelis P.C. Jager, Tim Frenzel, Roger Brüggemann, Prospective validation of a model‐informed precision dosing tool for vancomycin in intensive care patients, British Journal of Clinical Pharmacology, 10.1111/bcp.14360, 0, 0, (2020).
- Melissa Romano-Aguilar, Juan Eduardo Reséndiz-Galván, Susanna Edith Medellín-Garibay, Rosa del Carmen Milán-Segovia, Marco Ulises Martínez-Martínez, Carlos Abud-Mendoza, Silvia Romano-Moreno, Population pharmacokinetics of mycophenolic acid in Mexican patients with lupus nephritis, Lupus, 10.1177/0961203320931567, (096120332093156), (2020).
- Laurent M. A. Favié, Timo R. Haan, Yuma A. Bijleveld, Carin M. A. Rademaker, Toine C. G. Egberts, Debbie H. G. M. Nuytemans, Ron A. A. Mathôt, Floris Groenendaal, Alwin D. R. Huitema, Prediction of Drug Exposure in Critically Ill Encephalopathic Neonates Treated With Therapeutic Hypothermia Based on a Pooled Population Pharmacokinetic Analysis of Seven Drugs and Five Metabolites, Clinical Pharmacology & Therapeutics, 10.1002/cpt.1917, 0, 0, (2020).
- Robert B. Flint, Sinno H. P. Simons, Peter Andriessen, Kian D. Liem, Pieter L. J. Degraeuwe, Irwin K. M. Reiss, Rob Ter Heine, Aline G. J. Engbers, Birgit C. P. Koch, Ronald de Groot, David M. Burger, Catherijne A. J. Knibbe, Swantje Völler, The bioavailability and maturing clearance of doxapram in preterm infants, Pediatric Research, 10.1038/s41390-020-1037-9, (2020).
- Estelle Chasseloup, Gunnar Yngman, Mats O. Karlsson, Comparison of covariate selection methods with correlated covariates: prior information versus data information, or a mixture of both?, Journal of Pharmacokinetics and Pharmacodynamics, 10.1007/s10928-020-09700-5, (2020).
- Cornelis Smit, Anne M van Schip, Eric P A van Dongen, Roger J M Brüggemann, Matthijs L Becker, Catherijne A J Knibbe, Dose recommendations for gentamicin in the real-world obese population with varying body weight and renal (dys)function, Journal of Antimicrobial Chemotherapy, 10.1093/jac/dkaa312, (2020).
- Imad Kassem, Steven Sanche, Jun Li, Guillaume Bonnefois, Marie‐Pierre Dubé, Jean‐Lucien Rouleau, Jean‐Claude Tardif, Michel White, Jacques Turgeon, Fahima Nekka, Simon Denus, Population Pharmacokinetics of Candesartan in Patients with Chronic Heart Failure, Clinical and Translational Science, 10.1111/cts.12842, 0, 0, (2020).
- Eduard Schmulenson, Linda Krolop, Sven Simons, Susanne Ringsdorf, Yon-Dschun Ko, Ulrich Jaehde, Evaluation of patient-reported severity of hand–foot syndrome under capecitabine using a Markov modeling approach, Cancer Chemotherapy and Pharmacology, 10.1007/s00280-020-04128-7, (2020).
- Youwei Bi, Dinko Rekić, Miya O. Paterniti, Jianmeng Chen, Anshu Marathe, Badrul A. Chowdhury, Banu A. Karimi-Shah, Yaning Wang, A disease progression model of longitudinal lung function decline in idiopathic pulmonary fibrosis patients, Journal of Pharmacokinetics and Pharmacodynamics, 10.1007/s10928-020-09718-9, (2020).
- Alan Abdulla, Omar Rogouti, Nicole G. M. Hunfeld, Henrik Endeman, Annemieke Dijkstra, Teun van Gelder, Anouk E. Muller, Brenda C. M. de Winter, Birgit C. P. Koch, Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients, European Journal of Clinical Pharmacology, 10.1007/s00228-020-02873-5, (2020).
- Lien Ngo, Jaeseong Oh, Anhye Kim, Hyun‐moon Back, Won‐ho Kang, Jung‐woo Chae, Hwi‐yeol Yun, Howard Lee, Development of a Pharmacokinetic Model Describing Neonatal Fc Receptor‐Mediated Recycling of HL2351, a Novel Hybrid Fc‐Fused Interleukin‐1 Receptor Antagonist, to Optimize Dosage Regimen, CPT: Pharmacometrics & Systems Pharmacology, 10.1002/psp4.12555, 0, 0, (2020).
- Dorota Danielak, Michał Romański, Anna Kasprzyk, Artur Teżyk, Franciszek Główka, Population pharmacokinetic approach for evaluation of treosulfan and its active monoepoxide disposition in plasma and brain on the basis of a rat model, Pharmacological Reports, 10.1007/s43440-020-00115-0, (2020).
- Tomás Sou, Fadi Soukarieh, Paul Williams, Michael J. Stocks, Miguel Cámara, Christel A. S. Bergström, Model-Informed Drug Discovery and Development in Pulmonary Delivery: Biopharmaceutical Pharmacometric Modeling for Formulation Evaluation of Pulmonary Suspensions, ACS Omega, 10.1021/acsomega.0c03004, (2020).
- Ana Maria Araújo, Humberto Machado, Paula Guedes Pinho, Patrício Soares‐da‐Silva, Amílcar Falcão, Population Pharmacokinetic‐Pharmacodynamic Modeling for Propofol Anesthesia Guided by the Bispectral Index (BIS), The Journal of Clinical Pharmacology, 10.1002/jcph.1560, 60, 5, (617-628), (2019).
- Benayad Anass, Boutaous M'hamed, El Otmani Rabie, El Hakimi Abdelhadi, Touache Abdelhamid, Kamal R. Musa, Derdouri Salim, Refaa Zakariaa, Dennis A. Siginer, Simulation of crystallization evolution of polyoxymethylene during microinjection molding cycle, Polymers for Advanced Technologies, 10.1002/pat.4819, 31, 4, (838-852), (2019).
- Laura Pattison, James Mason, Anvay Deshpande, Evolving identity: from professional to medical student, The Clinical Teacher, 10.1111/tct.13116, 17, 4, (455-456), (2019).
- Malte Selch Larsen, Rasmus Vestergaard Juul, Shannon M. Zintner, Annemarie T. Kristensen, Paris Margaritis, Mads Kjelgaard‐Hansen, Bo Wiinberg, Ulrika S. H. Simonsson, Mads Kreilgaard, Rotational thromboelastometry can predict the probability of bleeding events in a translational rat model of haemophilia A following gene‐based FVIIa prophylaxis, Haemophilia, 10.1111/hae.13899, 26, 1, (164-172), (2019).
- Gopichand Gottipati, Alienor C. Berges, Shuying Yang, Chao Chen, Mats O. Karlsson, Elodie L. Plan, Item Response Model Adaptation for Analyzing Data from Different Versions of Parkinson’s Disease Rating Scales, Pharmaceutical Research, 10.1007/s11095-019-2668-6, 36, 9, (2019).
- Gustaf J. Wellhagen, Maria C. Kjellsson, Mats O. Karlsson, A Bounded Integer Model for Rating and Composite Scale Data, The AAPS Journal, 10.1208/s12248-019-0343-9, 21, 4, (2019).
- Jose Francis, Simbarashe P. Zvada, Paolo Denti, Mark Hatherill, Salome Charalambous, Stanley Mungofa, Rodney Dawson, Susan Dorman, Nikhil Gupte, Lubbe Wiesner, Amina Jindani, Thomas S. Harrison, Adeniyi Olagunju, Deirdre Egan, Andrew Owen, Helen M. McIlleron, A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine, Antimicrobial Agents and Chemotherapy, 10.1128/AAC.01964-18, 63, 4, (2019).
- Cindy J. Bednasz, Charles S. Venuto, Qing Ma, Eric S. Daar, Paul E. Sax, Margaret A. Fischl, Ann C. Collier, Kimberly Y. Smith, Camlin Tierney, Edward P. Acosta, Donald E. Mager, Gene D. Morse, Hector H. Bolivar, Sandra Navarro, Susan L. Koletar, Diane Gochnour, Edward Seefried, Julie Hoffman, Judith Feinberg, Michelle Saemann, Kristine Patterson, Donna Pittard, David Currin, Kerry Upton, Michael Saag, Graham Ray, Steven Johnson, Bartolo Santos, Connie A. Funk, Michael Morgan, Brenda Jackson, Pablo Tebas, Aleshia Thomas, Ge-Youl Kim, Michael K. Klebert, Jorge L. Santana, Santiago Marrero, Jane Norris, Sandra Valle, Gary Matthew Cox, Martha Silberman, Sadia Shaik, Ruben Lopez, Margie Vasquez, Demetre Daskalakis, Christina Megill, Todd Stroberg, Jessica Shore, Babafemi Taiwo, Mitchell Goldman, Molly Boston, Jeffrey Lennox, Carlos del Rio, Timothy W. Lane, Kim Epperson, Annie Luetkemeyer, Mary Payne, Barbara Gripshover, Dawn Antosh, Jane Reid, Mary Adams, Sheryl S. Storey, Shelia B. Dunaway, Joel Gallant, Ilene Wiggins, Kimberly Y. Smith, Joan A. Swiatek, Joseph Timpone, Princy Kumar, Ardis Moe, Maria Palmer, Jon Gothing, Joanne Delaney, Kim Whitely, Ann Marie Anderson, Scott M. Hammer, Michael T. Yin, Mamta Jain, Tianna Petersen, Roberto Corales, Christine Hurley, Keith Henry, Bette Bordenave, Amanda Youmans, Mary Albrecht, Richard B. Pollard, Abimbola Olusanya, Paul R. Skolnik, Betsy Adams, Karen T. Tashima, Helen Patterson, Michelle Ukwu, Lauren Rogers, Henry H. Balfour, Kathy A. Fox, Susan Swindells, Frances Van Meter, Gregory Robbins, Nicole Burgett-Yandow, Charles E. Davis, Colleen Boyce, William A. O’Brien, Gerianne Casey, Gene D. Morse, Chiu-Bin Hsaio, Jeffrey L. Meier, Jack T. Stapleton, Donna Mildvan, Manuel Revuelta, David Currin, Wafaa El Sadr, Avelino Loquere, Nyef El-Daher, Tina Johnson, Robert Gross, Kathyrn Maffei, Valery Hughes, Glenn Sturge, Deborah McMahon, Barbara Rutecki, Michael Wulfsohn, Andrew Cheng, Norbert Bischofberger, Lynn Dix, Qiming Liao, Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202, Antimicrobial Agents and Chemotherapy, 10.1128/AAC.01638-18, 63, 4, (2019).
- Xiao Zhu, David B. Finlay, Michelle Glass, Stephen B. Duffull, An intact model for quantifying functional selectivity, Scientific Reports, 10.1038/s41598-019-39000-z, 9, 1, (2019).
- Nadine Pinder, Johannes B. Zimmermann, Silke Gastine, Gudrun Würthwein, Georg Hempel, Thomas Bruckner, Torsten Hoppe-Tichy, Markus A. Weigand, Stefanie Swoboda, Continuous infusion of physostigmine in patients with perioperative septic shock: A pharmacokinetic/pharmacodynamic study with population pharmacokinetic modeling, Biomedicine & Pharmacotherapy, 10.1016/j.biopha.2019.109318, 118, (109318), (2019).
- Bojana Golubović, Katarina Vučićević, Dragana Radivojević, Sandra Vezmar Kovačević, Milica Prostran, Branislava Miljković, Exploring sirolimus pharmacokinetic variability using data available from the routine clinical care of renal transplant patients – population pharmacokinetic approach, Journal of Medical Biochemistry, 10.2478/jomb-2018-0030, 38, 3, (323-331), (2019).
- Theodoros Papathanasiou, Anders Deichmann Springborg, Kenneth Thermann Kongstad, Dan Staerk, Kirsten Møller, Bradley Kenneth Taylor, Trine Meldgaard Lund, Mads Utke Werner, High-dose naloxone, an experimental tool uncovering latent sensitisation: pharmacokinetics in humans, British Journal of Anaesthesia, 10.1016/j.bja.2018.12.007, (2019).
- Kentaro Oniki, Junji Saruwatari, A Multifaceted Approach regarding the Association of the DsbA-L Gene with the Risk of Obesity-related Diseases Based on Clinical Pharmacogenetics臨床薬理遺伝学に基づくDsbA-Lと肥満関連疾患予防に関する多角的検討, YAKUGAKU ZASSHI, 10.1248/yakushi.18-00163-3, 139, 1, (53-60), (2019).
- Theodoros Papathanasiou, Anders Strathe, Rune Viig Overgaard, Trine Meldgaard Lund, Andrew C. Hooker, Optimizing Dose-Finding Studies for Drug Combinations Based on Exposure-Response Models, The AAPS Journal, 10.1208/s12248-019-0365-3, 21, 5, (2019).
- Cornelis Smit, Roeland E. Wasmann, Marinus J. Wiezer, Hendricus P. A. van Dongen, Johan W. Mouton, Roger J. M. Brüggemann, Catherijne A. J. Knibbe, Tobramycin Clearance Is Best Described by Renal Function Estimates in Obese and Non-obese Individuals: Results of a Prospective Rich Sampling Pharmacokinetic Study, Pharmaceutical Research, 10.1007/s11095-019-2651-2, 36, 8, (2019).
- Corinne Seng Yue, Deniz Ozdin, Susannah Selber‐Hnatiw, Murray P. Ducharme, Opportunities and Challenges Related to the Implementation of Model‐Based Bioequivalence Criteria, Clinical Pharmacology & Therapeutics, 10.1002/cpt.1270, 105, 2, (350-362), (2019).
- Ronald Niebecker, Hugo Maas, Alexander Staab, Matthias Freiwald, Mats O. Karlsson, Modeling Exposure‐Driven Adverse Event Time Courses in Oncology Exemplified by Afatinib, CPT: Pharmacometrics & Systems Pharmacology, 10.1002/psp4.12384, 8, 4, (230-239), (2019).
- Matts Kågedal, Divya Samineni, William R. Gillespie, Dan Lu, Bernard M. Fine, Sandhya Girish, Chunze Li, Jin Y. Jin, Time‐to‐Event Modeling of Peripheral Neuropathy: Platform Analysis of Eight Valine‐Citrulline‐Monomethylauristatin E Antibody–Drug Conjugates, CPT: Pharmacometrics & Systems Pharmacology, 10.1002/psp4.12442, 8, 8, (606-615), (2019).
- João A. Abrantes, Alexander Solms, Dirk Garmann, Elisabet I. Nielsen, Siv Jönsson, Mats O. Karlsson, Bayesian Forecasting Utilizing Bleeding Information to Support Dose Individualization of Factor VIII, CPT: Pharmacometrics & Systems Pharmacology, 10.1002/psp4.12464, 8, 12, (894-903), (2019).
- Bart A.W. Jacobs, Maarten J. Deenen, Markus Joerger, Hilde Rosing, Niels Vries, Didier Meulendijks, Annemieke Cats, Jos H. Beijnen, Jan H.M. Schellens, Alwin D.R. Huitema, Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis, CPT: Pharmacometrics & Systems Pharmacology, 10.1002/psp4.12474, 8, 12, (940-950), (2019).
- Swantje Völler, Robert B Flint, Peter Andriessen, Karel Allegaert, Luc J I Zimmermann, Kian D Liem, Birgit C P Koch, Sinno H P Simons, Catherijne A J Knibbe, Rapidly maturing fentanyl clearance in preterm neonates, Archives of Disease in Childhood - Fetal and Neonatal Edition, 10.1136/archdischild-2018-315920, 104, 6, (F598-F603), (2019).
- Sabine F. Maarbjerg, Anders Thorsted, Anders Kristoffersson, Lena E. Friberg, Elisabet I. Nielsen, Mikala Wang, Birgitte Brock, Henrik Schrøder, Piperacillin pharmacokinetics and target attainment in children with cancer and fever: Can we optimize our dosing strategy?, Pediatric Blood & Cancer, 10.1002/pbc.27654, 66, 6, (2019).
- Swantje Völler, Robert B. Flint, Fouzi Beggah, Irwin Reiss, Peter Andriessen, Luc J.I. Zimmermann, John N. den Anker, Kian D. Liem, Birgit C.P. Koch, Saskia Wildt, Catherijne A.J. Knibbe, Sinno H.P. Simons, Recently Registered Midazolam Doses for Preterm Neonates Do Not Lead to Equal Exposure: A Population Pharmacokinetic Model, The Journal of Clinical Pharmacology, 10.1002/jcph.1429, 59, 10, (1300-1308), (2019).
- Panteleimon D. Mavroudis, John den Anker, Laurie S. Conklin, Jesse M. Damsker, Eric P. Hoffman, Kanneboyina Nagaraju, Paula R. Clemens, William J. Jusko, Population Pharmacokinetics of Vamorolone (VBP15) in Healthy Men and Boys With Duchenne Muscular Dystrophy, The Journal of Clinical Pharmacology, 10.1002/jcph.1388, 59, 7, (979-988), (2019).
- Feifan Xie, An Vermeulen, Pieter Colin, Zeneng Cheng, A semiphysiological population pharmacokinetic model of agomelatine and its metabolites in Chinese healthy volunteers, British Journal of Clinical Pharmacology, 10.1111/bcp.13902, 85, 5, (1003-1014), (2019).
- Anders Thorsted, Anders N Kristoffersson, Sabine F Maarbjerg, Henrik Schrøder, Mikala Wang, Birgitte Brock, Elisabet I Nielsen, Lena E Friberg, Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen, Journal of Antimicrobial Chemotherapy, 10.1093/jac/dkz270, (2019).
- Justin J. Wilkins, Yulia Vugmeyster, Isabelle Dussault, Pascal Girard, Akash Khandelwal, Population Pharmacokinetic Analysis of Bintrafusp Alfa in Different Cancer Types, Advances in Therapy, 10.1007/s12325-019-01018-0, (2019).
- Ahmed A. Suleiman, Mukul Minocha, Amit Khatri, Yinuo Pang, Ahmed A. Othman, Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I–III Clinical Trials, Clinical Pharmacokinetics, 10.1007/s40262-019-00759-z, (2019).
- Cornelis Smit, Roeland E. Wasmann, Sebastiaan C. Goulooze, Eric J. Hazebroek, Eric P. A. Van Dongen, Desiree M. T. Burgers, Johan W. Mouton, Roger J. M. Brüggemann, Catherijne A. J. Knibbe, A Prospective Clinical Study Characterizing the Influence of Morbid Obesity on the Pharmacokinetics of Gentamicin: Towards Individualized Dosing in Obese Patients, Clinical Pharmacokinetics, 10.1007/s40262-019-00762-4, (2019).
- Stijn W. van Beek, Rob ter Heine, Ron J. Keizer, Cecile Magis-Escurra, Rob E. Aarnoutse, Elin M. Svensson, Personalized Tuberculosis Treatment Through Model-Informed Dosing of Rifampicin, Clinical Pharmacokinetics, 10.1007/s40262-018-00732-2, (2019).
- Roeland E Wasmann, Cornelis Smit, Rob ter Heine, Simon E Koele, Eric P H van Dongen, René M J Wiezer, David M Burger, Catherijne A J Knibbe, Roger J M Brüggemann, Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adults, Journal of Antimicrobial Chemotherapy, 10.1093/jac/dky554, (2019).
- Didi Bury, Rob ter Heine, Ewoudt M. W. van de Garde, Marten R. Nijziel, Rene J. Grouls, Maarten J. Deenen, The effect of neutropenia on the clinical pharmacokinetics of vancomycin in adults, European Journal of Clinical Pharmacology, 10.1007/s00228-019-02657-6, (2019).
- Anushka Naidoo, Maxwell Chirehwa, Veron Ramsuran, Helen McIlleron, Kogieleum Naidoo, Nonhlanhla Yende-Zuma, Ravesh Singh, Sinaye Ncgapu, John Adamson, Katya Govender, Paolo Denti, Nesri Padayatchi, Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis, Pharmacogenomics, 10.2217/pgs-2018-0166, (2019).
- Stein Schalkwijk, Rob ter Heine, Angela Colbers, Edmund Capparelli, Brookie M Best, Tim R Cressey, Rick Greupink, Frans G M Russel, José Moltó, Mark Mirochnick, Mats O Karlsson, David M Burger, Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling, Journal of Antimicrobial Chemotherapy, 10.1093/jac/dky567, (2019).
- Nienke J. Vet, Brenda C. M. de Winter, Muriel Koninckx, Shelley A. Boeschoten, Annemie L. M. Boehmer, Jacintha T. Verhallen, Frans B. Plӧtz, Anja A. Vaessen-Verberne, Bart C. H. van der Nagel, Catherijne A. J. Knibbe, Corinne M. P. Buysse, Saskia N. de Wildt, Birgit C. P. Koch, Matthijs de Hoog, Population Pharmacokinetics of Intravenous Salbutamol in Children with Refractory Status Asthmaticus, Clinical Pharmacokinetics, 10.1007/s40262-019-00811-y, (2019).
- Robin Michelet, Lien Dossche, Charlotte Van Herzeele, Pauline De Bruyne, Elke Gasthuys, Jan Van Bocxlaer, Johan Vande Walle, An Vermeulen, An Integrated Paediatric Population PK/PD Analysis of dDAVP: How do PK Differences Translate to Clinical Outcomes?, Clinical Pharmacokinetics, 10.1007/s40262-019-00798-6, (2019).
- A. Brekkan, S. Jönsson, M. O. Karlsson, E. L. Plan, Handling underlying discrete variables with bivariate mixed hidden Markov models in NONMEM, Journal of Pharmacokinetics and Pharmacodynamics, 10.1007/s10928-019-09658-z, (2019).
- Susanna E. Medellin-Garibay, Nadia Hernández-Villa, Lourdes Cecilia Correa-González, Miriam Nayeli Morales-Barragán, Karla Paulina Valero-Rivera, Juan Eduardo Reséndiz-Galván, Juan José Ortiz-Zamudio, Rosa del Carmen Milán-Segovia, Silvia Romano-Moreno, Population pharmacokinetics of methotrexate in Mexican pediatric patients with acute lymphoblastic leukemia, Cancer Chemotherapy and Pharmacology, 10.1007/s00280-019-03977-1, (2019).
- Ali A. Alhadab, Joshua Rhein, Lillian Tugume, Abdu Musubire, Darlisha A. Williams, Mahsa Abassi, Melanie R. Nicol, David B. Meya, David R. Boulware, Richard C. Brundage, Pharmacokinetics-pharmacodynamics of sertraline as an antifungal in HIV-infected Ugandans with cryptococcal meningitis, Journal of Pharmacokinetics and Pharmacodynamics, 10.1007/s10928-019-09657-0, (2019).
- Sebastiaan C. Goulooze, Swantje Völler, Pyry A. J. Välitalo, Elisa A. M. Calvier, Leon Aarons, Elke H. J. Krekels, Catherijne A. J. Knibbe, The Influence of Normalization Weight in Population Pharmacokinetic Covariate Models, Clinical Pharmacokinetics, 10.1007/s40262-018-0652-7, 58, 1, (131-138), (2018).
- Ida Netterberg, Chi‐Chung Li, Luciana Molinero, Nageshwar Budha, Siddharth Sukumaran, Mark Stroh, E. Niclas Jonsson, Lena E. Friberg, A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab‐Treated non‐small Cell Lung Cancer Patients, Clinical Pharmacology & Therapeutics, 10.1002/cpt.1198, 105, 2, (486-495), (2018).
- Juan Eduardo Reséndiz‐Galván, Susanna Edith Medellín‐Garibay, Rosa del Carmen Milán‐Segovia, Perla del Carmen Niño‐Moreno, Javier Isordia‐Segovia, Silvia Romano‐Moreno, Dosing recommendations based on population pharmacokinetics of tacrolimus in Mexican adult patients with kidney transplant, Basic & Clinical Pharmacology & Toxicology, 10.1111/bcpt.13138, 124, 3, (303-311), (2018).
- E W Muilwijk, J A Maertens, W J F M van der Velden, R ter Heine, A Colbers, D M Burger, D Andes, K Theunissen, N M A Blijlevens, R J M Brüggemann, Pharmacokinetics of extended dose intervals of micafungin in haematology patients: optimizing antifungal prophylaxis, Journal of Antimicrobial Chemotherapy, 10.1093/jac/dky324, 73, 11, (3095-3101), (2018).
- Chunli Chen, Sebastian G. Wicha, Rikard Nordgren, Ulrika S. H. Simonsson, Comparisons of Analysis Methods for Assessment of Pharmacodynamic Interactions Including Design Recommendations, The AAPS Journal, 10.1208/s12248-018-0239-0, 20, 4, (2018).
- Valentina Topić Vučenović, Zvezdana Rajkovača, Dijana Jelić, Dragi Stanimirović, Goran Vuleta, Branislava Miljković, Katarina Vučićević, Investigation of factors influencing radioiodine (131I) biokinetics in patients with benign thyroid disease using nonlinear mixed effects approach, European Journal of Clinical Pharmacology, 10.1007/s00228-018-2459-8, 74, 8, (1037-1045), (2018).
- Ralf-Dieter Hilgers, Malgorzata Bogdan, Carl-Fredrik Burman, Holger Dette, Mats Karlsson, Franz König, Christoph Male, France Mentré, Geert Molenberghs, Stephen Senn, Lessons learned from IDeAl — 33 recommendations from the IDeAl-net about design and analysis of small population clinical trials, Orphanet Journal of Rare Diseases, 10.1186/s13023-018-0820-8, 13, 1, (2018).
- Anne van Rongen, Marloes P. van der Aa, Maja Matic, Ron H. N. van Schaik, Vera H. M. Deneer, Marja M. van der Vorst, Catherijne A. J. Knibbe, Increased Metformin Clearance in Overweight and Obese Adolescents: A Pharmacokinetic Substudy of a Randomized Controlled Trial, Pediatric Drugs, 10.1007/s40272-018-0293-1, 20, 4, (365-374), (2018).
- Jesmin Permala Lohy Das, Myat P. Kyaw, Myat H. Nyunt, Khin Chit, Kyin H. Aye, Moe M. Aye, Mats O. Karlsson, Martin Bergstrand, Joel Tarning, Population pharmacokinetic and pharmacodynamic properties of artesunate in patients with artemisinin sensitive and resistant infections in Southern Myanmar, Malaria Journal, 10.1186/s12936-018-2278-5, 17, 1, (2018).
- Malte Selch Larsen, Rasmus Vestergaard Juul, Andreas Velsing Groth, Ulrika S.H. Simonsson, Annemarie T. Kristensen, Tom Knudsen, Henrik Agersø, Mads Kreilgaard, Prediction of human pharmacokinetics of activated recombinant factor VII and B-domain truncated factor VIII from animal population pharmacokinetic models of haemophilia, European Journal of Pharmaceutical Sciences, 10.1016/j.ejps.2018.01.035, 115, (196-203), (2018).
- See more







